[go: up one dir, main page]

WO2000052145A3 - Embryonic or stem-like cell lines produced by cross species nuclear transplantation - Google Patents

Embryonic or stem-like cell lines produced by cross species nuclear transplantation Download PDF

Info

Publication number
WO2000052145A3
WO2000052145A3 PCT/US2000/005434 US0005434W WO0052145A3 WO 2000052145 A3 WO2000052145 A3 WO 2000052145A3 US 0005434 W US0005434 W US 0005434W WO 0052145 A3 WO0052145 A3 WO 0052145A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
embryonic
stem
cell
nuclear transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/005434
Other languages
French (fr)
Other versions
WO2000052145A2 (en
Inventor
James Robl
Jose Cibell
Steven L Stice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Priority to AU33913/00A priority Critical patent/AU3391300A/en
Priority to IL14515100A priority patent/IL145151A0/en
Priority to JP2000602757A priority patent/JP2002537803A/en
Priority to EP00912131A priority patent/EP1159404A2/en
Priority to BR0008714-9A priority patent/BR0008714A/en
Priority to CA002364415A priority patent/CA2364415A1/en
Publication of WO2000052145A2 publication Critical patent/WO2000052145A2/en
Publication of WO2000052145A3 publication Critical patent/WO2000052145A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

An improved method of nuclear transfer involving the transplantation of differentiated donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation. Also, methods for improving nuclear transfer efficiency by genetically altering donor cells to inhibit apoptosis, select for a specific cell cycle and/or enhance embryonic growth and development are provided.
PCT/US2000/005434 1999-03-02 2000-03-02 Embryonic or stem-like cell lines produced by cross species nuclear transplantation Ceased WO2000052145A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU33913/00A AU3391300A (en) 1999-03-02 2000-03-02 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
IL14515100A IL145151A0 (en) 1999-03-02 2000-03-02 Embr0yonic or stem-like cell lines produced by cross species nuclear transplantation
JP2000602757A JP2002537803A (en) 1999-03-02 2000-03-02 Embryonic or stem-like cell lines produced by xenogeneic nuclear transfer
EP00912131A EP1159404A2 (en) 1999-03-02 2000-03-02 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
BR0008714-9A BR0008714A (en) 1999-03-02 2000-03-02 Embryonic or stem cell lines produced by cross-species nuclear transplant
CA002364415A CA2364415A1 (en) 1999-03-02 2000-03-02 Embryonic or stem-like cell lines produced by cross species nuclear transplantation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26046899A 1999-03-02 1999-03-02
US09/260,468 1999-03-02

Publications (2)

Publication Number Publication Date
WO2000052145A2 WO2000052145A2 (en) 2000-09-08
WO2000052145A3 true WO2000052145A3 (en) 2001-01-04

Family

ID=22989289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005434 Ceased WO2000052145A2 (en) 1999-03-02 2000-03-02 Embryonic or stem-like cell lines produced by cross species nuclear transplantation

Country Status (8)

Country Link
EP (1) EP1159404A2 (en)
JP (1) JP2002537803A (en)
AU (1) AU3391300A (en)
BR (1) BR0008714A (en)
CA (1) CA2364415A1 (en)
IL (1) IL145151A0 (en)
NZ (1) NZ513888A (en)
WO (1) WO2000052145A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466203A1 (en) * 2001-11-06 2003-05-15 Shanghai Second Medical University Cross-species somatic cell nuclear transfer using rabbit oocyte
JP2005523685A (en) * 2001-11-06 2005-08-11 上海第二医科大学 Somatic embryonic stem cells and their differentiated progeny
WO2003054146A2 (en) 2001-11-14 2003-07-03 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US20030113910A1 (en) * 2001-12-18 2003-06-19 Mike Levanduski Pluripotent stem cells derived without the use of embryos or fetal tissue
AU2003215280A1 (en) 2002-02-15 2003-09-09 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
AU2003254298A1 (en) 2002-08-02 2004-02-23 Stratatech Corporation Species specific dna detection
AU2003262760A1 (en) 2002-08-21 2004-03-11 Northwestern University Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
US7683025B2 (en) 2002-11-14 2010-03-23 Northwestern University Synthesis and self-assembly of ABC triblock bola peptide amphiphiles
KR20050100397A (en) 2003-02-11 2005-10-18 노오쓰웨스턴 유니버시티 Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
EP2314305A3 (en) 2003-12-05 2011-08-10 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
MXPA06006387A (en) 2003-12-05 2006-09-04 Univ Northwestern Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof.
US20050214257A1 (en) 2003-12-23 2005-09-29 Northwestern University Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation
US8637065B2 (en) 2004-07-09 2014-01-28 William Marsh Rice University Dermis-derived cells for tissue engineering applications
WO2006096614A2 (en) 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
AU2007234365A1 (en) * 2006-04-05 2007-10-11 William Marsh Rice University A shape-based approach for scaffoldless tissue engineering
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
RU2352637C1 (en) * 2007-06-21 2009-04-20 Александр Сергеевич Тепляшин Method of obtaining of hybrid human stem cell
KR20120012811A (en) 2009-04-13 2012-02-10 노오쓰웨스턴 유니버시티 Novel peptide-based scaffolds for cartilage regeneration and methods of using them
WO2016044721A1 (en) 2014-09-19 2016-03-24 Regenerative Medical Solutions, Inc. Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells
WO2016118824A1 (en) 2015-01-22 2016-07-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007841A1 (en) * 1996-08-19 1998-02-26 University Of Massachusetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
WO2000029602A1 (en) * 1998-11-13 2000-05-25 Cedars-Sinai Medical Center Transfection of male germ cells for generation of selectable transgenic stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007841A1 (en) * 1996-08-19 1998-02-26 University Of Massachusetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
WO2000029602A1 (en) * 1998-11-13 2000-05-25 Cedars-Sinai Medical Center Transfection of male germ cells for generation of selectable transgenic stem cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. JURISICOVA ET AL.: "EXPRESSION AND REGULATION OF GENES ASSOCIATED WITH CELL DEATH DURING MURINE PREIMPLANTATION EMBRYO DEVELOPMENT.", MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 51, November 1998 (1998-11-01), NEW YOK, N.Y., US, pages 243 - 253, XP000952608 *
A. TROUNSON ET AL.: "POTENTIAL BENEFITS OF CELL CLONING FOR HUMAN MEDICINE.", REPRODUCTION FERTILITY AND DEVELOPMENT, vol. 10, 1998, pages 121 - 125, XP000952550 *
L. BERGSON ET AL.: "DEFECTS IN REGULATION OF APOPTOSIS IN CASPASE DEFICIENT MICE.", GENES & DEVELOPMENT, vol. 12, 1 May 1998 (1998-05-01), NEW YORK, N.Y., US, pages 1304 - 1314, XP000952591 *
S. ARSENIAN ET AL.: "SERUM RESPONSE FACTOR IS ESSENTIAL FOR MESODERM FORMATION DURING MOUSE EMBRYOGENESIS.", THE EMBO JOURNAL., vol. 17, no. 21, 2 November 1998 (1998-11-02), EYNSHAM, OXFORD, GB, pages 6289 - 6299, XP002149683 *
W. CAI ET AL.: "SEQUENCE AND TRANSCRIPTION OF Qa-2-ENCODING GENES IN MOUSE LYMPHOCYTES AND BLASTOCYSTS.", IMMUNOGENETICS, vol. 45, no. 2, 1996, NEW YORK, N.Y., US, pages 97 - 107, XP000952557 *

Also Published As

Publication number Publication date
IL145151A0 (en) 2002-06-30
CA2364415A1 (en) 2000-09-08
EP1159404A2 (en) 2001-12-05
AU3391300A (en) 2000-09-21
JP2002537803A (en) 2002-11-12
WO2000052145A2 (en) 2000-09-08
NZ513888A (en) 2001-09-28
BR0008714A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2000052145A3 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation
Gémes-Juhász et al. Effect of optimal stage of female gametophyte and heat treatment on in vitro gynogenesis induction in cucumber (Cucumis sativus L.)
Tsunoda et al. Effect of cutting the zona pellucida on the pronuclear transplantation in the mouse
BR9908499A (en) Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
NZ336612A (en) Cloning using donor nuclei from proliferating somatic cells
CN110301353B (en) Methods of Proliferation and Maintenance Culture of Masson Pine Embryogenic Callus
WO2001046401A8 (en) Embryonic or stem-like cells produced by cross species nuclear transplantation
NZ516236A (en) Altering life span of a recipient cell by transferring cell cytoplasm from a donor cell for use in gene therapy and cloning
EP0945515A3 (en) Production of proteins using homologous recombination
CA2388811A1 (en) Techniques for growth and differentiation of human pluripotent stem cells
CN106676075A (en) PG-haESCs (parthenogenetic-haploid embryonic stem cells) as well as preparation and application thereof
WO2000056905A3 (en) Method for enhancing and/or improving plant growth and/or yield or modifying plant architecture
Makowska et al. The effect of copper on plant regeneration in barley microspore culture.
DE60040134D1 (en)
Suzuki et al. Effect of genetic background on establishment of mouse embryonic stem cells
CN101121940A (en) A method for Agrobacterium-mediated transformation of switchgrass
MXPA00010473A (en) Process for obtaining stem cells.
CN103088059A (en) Efficient genetic transformation method of hybridized tulip tree
CN117402910A (en) Application of PP2C01 gene in regulation and control of salt tolerance of rice
WO2003057836A3 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
NIIZEKI et al. Callus formation from isolated protoplasts of apple, Malus pumila Mill
Ueda et al. Fusion studies of pollen protoplasts and generative cell protoplasts in Lilium longiflorum
EP0859059A3 (en) Methods and materials for introducing exogenous genes into cultured cells or fertilized eggs
BR0013999A (en) Embryonic or stem cell-like cell lines produced by cross-species nuclear transplantation and methods to improve embryonic development by genetic alteration of donor cells or by tissue culture conditions
Navrátilová et al. Biotechnological methods utilized in Cucumis research-A review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 145151

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2364415

Country of ref document: CA

Ref document number: 2364415

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 513888

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020017011132

Country of ref document: KR

Ref document number: PA/A/2001/008848

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 602757

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 33913/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000912131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 00806980.8

Country of ref document: CN

WWW Wipo information: withdrawn in national office

Ref document number: 2000912131

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000912131

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017011132

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011132

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642